About Contact Us Privacy Policy Corrections
Tuesday, November 17, 2026

Punjab Orders Immediate Recall of Five Injections After Safety Tests Fail

The Punjab government has ordered the immediate recall of five injectable medicines after laboratory tests found them to be substandard or adulterated. The order covers specific batches of the five products, and pharmacies, hospitals and distributors across the province have been told to stop dispensing them at once.

The recall was set out in a public notice issued by the Directorate of Drugs Control on 13 November, in which the Provincial Quality Control Board directed that the affected batches be withdrawn from the market without delay. The board acted on laboratory findings, and its instruction leaves no room for the batches to remain on shelves while further checks are carried out.

The five medicines named in the notice are Injection Dormicum, Injection Davilax, Injection Zeftrox, Injection PSOL 2mL and Injection PSOL 10mL. Each was linked to a named batch and a named manufacturer, and the reasons for the action differ from one product to another. What they share is a failure to meet the quality standards that injectable medicines must satisfy before they reach patients.

Two batches of Injection Dormicum, numbered 47447 and 47661 and manufactured by Martin Dow Marker Ltd., were declared substandard after visible particulate matter was detected in them. Particles that can be seen in an injectable medicine are a serious defect, because the liquid is delivered straight into the body. The finding alone was enough for the batches to be pulled.

Injection Davilax, batch DD1126, manufactured by Unison Chemical Works, was declared adulterated, a separate and graver category of failure. An adulterated medicine is one whose composition does not match what it claims to be, and regulators treat that finding with particular severity.

Injection Zeftrox, batch 677, manufactured by Zafa Pharmaceutical Laboratories (Pvt.) Ltd., was found substandard following sterility testing, as was Injection PSOL 2mL, batch AK164, manufactured by Pharmasol Private Ltd. A sterility failure means the product cannot be shown to be free of living micro-organisms, and for a medicine that bypasses the body’s natural defences that is a defect which cannot be overlooked.

Injection PSOL 10mL, batch VL277, also manufactured by Pharmasol Private Ltd., was declared substandard because visible particulate matter was found in it, the same fault identified in the Dormicum batches. With two products from the same manufacturer affected, the notice points to quality problems beyond a single isolated batch.

The directorate has directed the manufacturers and the marketing authorisation holders to recall the affected batches immediately. They must also provide complete distribution records, so the authorities can trace where every unit went, and carry out root-cause analyses to establish how the faults arose. Each company must also submit a Corrective and Preventive Action plan, known as a CAPA plan, setting out what will change to stop the same failure happening again.

Pharmacies, medical stores, wholesalers, distributors and healthcare facilities across Punjab have been instructed to stop dispensing the affected batches at once. They must also report their remaining stock and consumption records to the drug inspectors concerned, so the authorities can account for what has been sold and what is still on shelves.

Drug regulatory authorities have also been directed to strengthen surveillance of the pharmaceutical supply chain and to take action under the Drugs Act, 1976, and the DRAP Act, 2012. The two laws give the authorities the powers they need to act against substandard and adulterated medicines, and the reference to both in the notice signals that enforcement will follow the recall rather than stopping at it.

For patients, the directorate’s message is direct: stop using the affected batches, because continued use may pose health risks. Anyone who has one of these injections at home should check the batch number on the packaging against the numbers in the notice, and ask a pharmacist or doctor if unsure.

Healthcare professionals and consumers have also been advised to report any related adverse drug reactions to the Provincial Pharmacovigilance Centre at the Directorate of Drugs Control, Punjab. Reports of that kind help the authorities judge whether patients have already been harmed and whether the recall has caught the problem in time. The system depends on people speaking up when something goes wrong, and the centre exists to receive exactly those reports.

The recall is a reminder of why injectable medicines are held to a higher standard than most other products. An injection that carries particles or living organisms goes directly into the bloodstream or tissue, where the body has little chance to defend itself. That is why sterility failures and visible particles are treated as serious defects, and why the response is immediate withdrawal rather than a warning.

What happens next will depend on how fully the recall is carried out. The manufacturers must account for their stock, the sellers must report what they hold, and the inspectors must check that the batches have genuinely left the market. If that chain works, the affected batches will disappear from Punjab’s pharmacies and hospitals. If it does not, the risk remains, and the directorate’s call for stronger surveillance suggests it knows the job is not finished when the notice is issued.

Maryam Batool

Staff writer at DailyUpdate47, covering breaking news and developing stories.